Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Retained Earnings (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of Retained Earnings data on record, last reported at -$69000.0 in Q3 2025.

  • For Q3 2025, Retained Earnings rose 99.98% year-over-year to -$69000.0; the TTM value through Sep 2025 reached -$69000.0, up 99.98%, while the annual FY2024 figure was -$387.4 million, 68.14% down from the prior year.
  • Retained Earnings reached -$69000.0 in Q3 2025 per ZBIO's latest filing, up from -$473.2 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$69000.0 in Q3 2025 and bottomed at -$473.2 million in Q2 2025.
  • Average Retained Earnings over 3 years is -$307.8 million, with a median of -$361.1 million recorded in 2024.
  • Peak YoY movement for Retained Earnings: plummeted 68.14% in 2024, then skyrocketed 99.98% in 2025.
  • A 3-year view of Retained Earnings shows it stood at -$230.4 million in 2023, then crashed by 68.14% to -$387.4 million in 2024, then skyrocketed by 99.98% to -$69000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$69000.0 in Q3 2025, -$473.2 million in Q2 2025, and -$421.0 million in Q1 2025.